ArticleJournal of neurointerventional surgery2026
Intracranial Dotter angioplasty using Tenzing (Tenzingplasty) for acute ischemic stroke with underlying intracranial atherosclerotic disease.
Article in Journal of neurointerventional surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCatheter-mediated (Dotter) angioplasty has been previously described for extracranial/peripheral arteries. Tenzing (Route 92 Medical, San Mateo, California, USA), a shelf-reducing delivery catheter, has an atraumatic tapered distal tip that progressively enlarges to maximal outer diameter of 1.2 mm (Tenzing 5), 1.6 mm (Tenzing 7), and 2.1 mm (Tenzing 8).
objectiveTo report our initial experience treating acutely symptomatic intracranial atherosclerotic disease (ICAD) using Dotter angioplasty with Tenzing (Tenzingplasty).
methodsAfter institutional review board approvals, we retrospectively reviewed clinical and procedural data of patients with underlying ICAD treated with off-label Tenzingplasty between 2022 and 2025, either as part of endovascular treatment for large vessel occlusion, or after medical therapy failure <96 hours from presentation.
resultsWe identified 53 consecutive patients with symptomatic ICAD who underwent Tenzingplasty, median (IQR) age 63 (57-70) years, 29 (55%) male. ICAD locations were: M1 (24), M2 (9), internal carotid artery (3), vertebral V4 segment (7), basilar (8), vertebrobasilar junction (1), and A2 anterior cerebral artery (1). First pass aspiration thrombectomy for patients with an initial modified Thrombolysis in Cerebral Infarction score 0 (without crossing the ICAD lesion) was performed in 34/53 (64%). After median 1 (IQR 1-2) Tenzingplasty pass, median (IQR) stenosis improved from 100% (95-100) to 60% (42-76) post-Tenzingplasty (P<0.0001). Subsequent balloon angioplasty or stenting was performed in 4% and 21%, respectively. Successful final reperfusion (expanded Thrombolysis in Cerebral Infarction 2b-3) was achieved in 81%, with one Tenzingplasty-related complication (a non-flow limiting dissection), and no perforations. In follow up, 25/44 (57%) had a 90-day modified Rankin Scale score of 0-2.
conclusionTenzingplasty may be a feasible and safe rescue therapy for improving luminal caliber, flow restoration, and/or lesion preparation for stenting in acutely symptomatic ICAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.